Search results for " antiphospholipid syndrome"

showing 6 items of 6 documents

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues

2006

In this study, by using different techniques (i.e. Northern blot hybridization, RT-PCR and Southern blot hybridization) on various normal rat tissues, we were able to identify liver, kidney, heart, small intestine, brain, spleen, stomach and prostate as tissues in which the ApoH gene is transcribed. Moreover, for some of these tissues, by in situ hybridization, we found a specific localization of apoH transcripts. For instance epithelial cells of the bile ducts in liver and of the proximal tubules in kidney are the major sites of apoH synthesis. Our data suggest that some of the different physiological roles proposed for apoH could correlate with its direct expression, while others could co…

In situ hybridizationBiologyß-2-glycoprotein I apoH antiphospholipid syndrome Fanconi syndromeKidneyGeneticsmedicineAnimalsHumansBeta 2-Glycoprotein ITissue DistributionRNA MessengerNorthern blotRats WistarCells CulturedIn Situ HybridizationGlycoproteinsSouthern blotReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingMyocardiumKidney metabolismGeneral MedicineMolecular biologySmall intestineRatsJejunumReal-time polymerase chain reactionmedicine.anatomical_structureLiverbeta 2-Glycoprotein IApolipoprotein H
researchProduct

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

2021

Antiphospholipid syndrome (APS) is frequently associated with thrombocytopenia, in most cases mild and in the absence of major bleedings. In some patients with a confirmed APS diagnosis, secondary immune thrombocytopenia (ITP) may lead to severe thrombocytopenia with consequent major bleeding. At the same time, the presence of antiphospholipid antibodies (aPL) in patients with a diagnosis of primary ITP has been reported in several studies, although with some specific characteristics especially related to the variety of antigenic targets. Even though it does not enter the APS defining criteria, thrombocytopenia should be regarded as a warning sign of a “high risk” APS and thus thoroughly ev…

Pediatricsmedicine.medical_specialtyQH301-705.5medicine.drug_classMedicine (miscellaneous)thrombocytopeniaReviewGeneral Biochemistry Genetics and Molecular BiologyAntigenimmune system diseasesAntiphospholipid syndromehemic and lymphatic diseasesmedicineBiology (General)Antiphospholipid antibodies Antiphospholipid syndrome Immune thrombocytopenia Lupus anticoagulant ThrombocytopeniaLupus anticoagulantbiologybusiness.industryAnticoagulantantiphospholipid antibodiesmedicine.diseaseThrombosisImmune thrombocytopeniaVenous thrombosislupus anticoagulantimmune thrombocytopeniabiology.proteinAntibodybusinessAntiphospholipid antibodieantiphospholipid syndromeBiomedicines
researchProduct

Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19

2021

Abstract Background Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome—microvascular thrombosis, stroke, and venous and pulmonary clots—are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID‐19 patients, but their association with the clinical course of COVID‐19 remains unproven. Objectives To analyze the presence and relevance of lipid‐binding aPL in hospitalized COVID‐19 patients. Methods Two cohorts of 53 and 121 patients from a single center hospitalized for PCR‐proven severe acute respiratory syndro…

VASCULAR BIOLOGYInflammationCatastrophic antiphospholipid syndromeblood coagulation disorderendothelial protein C receptorMiceCOVID‐19immune system diseasesAntiphospholipid syndromeCoagulopathyAnimalsHumansMedicineneoplasmsEndothelial protein C receptorbiologySARS-CoV-2business.industryantiphospholipid antibodiesCOVID-19Endothelial CellsOriginal ArticlesHematologyAntiphospholipid Syndromemedicine.diseaseThrombosisinflammationImmunologyAntibodies Antiphospholipidbiology.proteinOriginal ArticleAntibodymedicine.symptomBlood coagulation disorderbusinessJournal of Thrombosis and Haemostasis
researchProduct

Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications

2018

Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) antibodies. There is sound evidence that aPL act as pathogenic autoantibodies being responsible for vascular clots and miscarriages. However, the exact mechanisms involved in the clinical manifestations of the syndrome are still a matter of investigation. In particular, while vascular thrombosis is apparently not associated with inflammation, the pathogenesis of miscarriages can be explained only in part by the aPL-mediated hypercoagulable state and additional non-thrombotic effects, including placental inflammation, have b…

lcsh:Immunologic diseases. Allergy0301 basic medicineImmunologyComplementMiscarriagesAnti-beta2 glycoprotein I antibodieInflammationMiscarriagePathogenesis03 medical and health sciences0302 clinical medicineImmune systemAntiphospholipid syndromeimmune system diseasesAntiphospholipid syndromeMedicineImmunology and AllergyAnimal model030203 arthritis & rheumatologyAutoimmune diseaseInflammationbusiness.industryAutoantibodyThrombosismedicine.diseaseComplement (complexity)Complement systemAnimal models030104 developmental biologyAnti-beta2 glycoprotein I antibodiesPerspectiveThrombosiImmunologyAnimal models; Anti-beta2 glycoprotein I antibodies; Antiphospholipid syndrome; Complement; Inflammation; Miscarriages; Therapy; Thrombosis; Immunology and Allergy; ImmunologyTherapymedicine.symptomlcsh:RC581-607businessFrontiers in Immunology
researchProduct

THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers

2016

Background Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome [1]. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokines storm the latter contributing to the development of multi-organ failure [2]. Objectives In the current study, we aimed to investigate clinical data, treatments, and outcome of adult MAS patients secondary to autoimmune rheumatic disease. Methods We retrospectively investigated clinical data, treatments, and outcome of 40 adult MAS patients secondary to autoimmune rheumatic disease…

medicine.medical_specialtyImmunologyCatastrophic antiphospholipid syndromeGastroenterologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundTocilizumabRheumatologyInternal medicinemedicineImmunology and AllergyMacrophage activation syndrome adult onset Still‟s disease hyperferritinemic syndromebusiness.industrySeptic shockProportional hazards modelMortality ratehyperferritinemic syndromeadult onset Still‟s diseasemedicine.diseaseComorbiditySurgeryMethylprednisolonechemistryMacrophage activation syndromeMacrophage activation syndromebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct